

Substitute for form 1449B/PTO

**FIFTH SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT****IN AN APPLICATION****TESTING OF REFERENCES**

May 13, 2008

(Use several sheets if necessary)

ATTORNEY DOCKET NO.

2907.1000-003

APPLICATION NO.

10/686,943

FIRST NAMED INVENTOR

Andrew McMichael

FILING DATE

October 16, 2003

EXAMINER

Louise Humphrey, Ph.D.

CONFIRMATION NO.

4585

GROUP

1648

**U.S. PATENT DOCUMENTS**

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/L.H./	A7	2001/0036928 A1	11-01-2001	Chamberlain, <i>et al.</i>

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
/L.H./	B13	WO 99/41383 A1	08/19/1999	Maxygen, Inc.		
	B14	WO 02/24224 A2	03/28/2002	Oxxon Pharmaccines Limited		
	B15	WO 2005/026370 A2	03/24/2005	Aventis Pasteur Limited and Therion Biologics, Inc.		
	B16	WO 2006/061643 A1	06/15/2006	Oxxon Therapeutics Ltd.		
	B17	WO 2006/120474 A2	11/16/2006	Oxxon Therapeutics Ltd.		
	B18	WO 2006/125983 A1	11/30/2006	Oxxon Therapeutics Ltd.		
	B19	CN 1 324 661 A	12/05/2001	Second Military Medical University, PLA		X

EXAMINER /Louise Humphrey/

DATE CONSIDERED

07/02/2008

Substitute for form 1449B/PTO  <b>FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>LISTING OF REFERENCES</b>  <b>May 13, 2008</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003		APPLICATION NO. 10/686,943	
	FIRST NAMED INVENTOR Andrew McMichael		FILING DATE October 16, 2003	
	EXAMINER Louise Humphrey, Ph.D.	CONFIRMATION NO. 4585	GROUP 1648	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/L.H./	AT9	SYFPEITHI Database, "Find Your Motif," [online], [retrieved on 2006-09-01]. Retrieved from the Internet <URL:http://www.syfpeithi.de/Scripts/MHCServer.dll/FindYourMotif.htm>.
	AS10	The Schlom Declaration cited in the Notice of Opposition to a European Patent. Patent No.: EP0979284 [Date signed by Declarant: Sept. 24, 2003; Date signed by Opponent: Oct. 2, 2003; Date filed in EPO: Oct. 2, 2003]
	AT10	The Gritz Declaration cited in the Notice of Opposition to a European Patent. Patent No.: EP0979284 [Date signed by Opponent: Oct. 2, 2003; Date filed in EPO: Oct. 2, 2003].
	AU10	The Chamberlain Declaration cited in the Notice of Opposition to a European Patent. Patent No.: EP0979284 [Date signed by Opponent: Oct. 2, 2003; Date filed in EPO: Oct. 2, 2003]
	C37	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416. Opponent: Transgene S.A. (English translation attached.) [Date signed by Opponent: Feb. 3, 2006 ; Date filed in EPO: Feb. 6, 2006]
	C38	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416 B1. Opponent: Merck & Co., Inc. [Date signed by Opponent: Feb. 9, 2006 ; Date filed in EPO: Feb. 13, 2006]
	C39	Notice of Opposition to a European Patent. Patent No.: EP 1 214 416 B1. Opponent: Crucell Holland B.V. [Date signed by Opponent: Feb. 6, 2006 ; Date filed in EPO: Feb. 13, 2006]
	C90	Chow, Y-H., <i>et al.</i> , "Improvement of Hepatitis B Virus DNA Vaccines by Plasmids Coexpressing Hepatitis B Surface Antigen and Interleukin-2," <i>J. Virol.</i> , 71(1): 169-178 (1997).
	C91	Haigwood, N.L., "Predictive Value of Primate Models for AIDS," <i>AIDS Reviews</i> 6: 187-198 (2004).
↓	C92	Hutchings, C.L., <i>et al.</i> , "Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity," <i>J. Immunol.</i> , 175: 599-606 (2005).

EXAMINER /Louise Humphrey/	DATE CONSIDERED 07/02/2008
----------------------------	----------------------------

Substitute for form 1449B/PTO  <b>FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>  <b>LISTING OF REFERENCES</b>  <b>May 13, 2008</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003		APPLICATION NO. 10/686,943	
	FIRST NAMED INVENTOR Andrew McMichael		FILING DATE October 16, 2003	
	EXAMINER Louise Humphrey, Ph.D.	CONFIRMATION NO. 4585	GROUP 1648	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/L.H./	C93	Lindsey, K.R., <i>et al.</i> , "Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma," <i>Clin. Cancer Res.</i> , 12(8): 2526-2537 (2006).
	C94	Marshall, J.L., <i>et al.</i> , "Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti-Carcinoembryonic Antigen Immune Responses," <i>J. Clin. Oncol.</i> , 18(23): 3964-3973 (2000).
	C95	Rosenberg, S.A., <i>et al.</i> , "Recombinant Fowlpox Viruses Encoding the Anchor-Modified gp100 Melanoma Antigen can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma," <i>Clin. Cancer Res.</i> , 9(8): 2973-2980 (2003).
	C96	Tagawa, S.T., <i>et al.</i> , "Phase I Study of Intranodal Delivery of a Plasmid DNA Vaccine for Patients with Stage IV Melanoma," <i>Cancer</i> , 98(1): 144-154 (2003).
	C97	Tomiyama, H., <i>et al.</i> , "Different Effects of Nef-Mediated HLA Class I Down-Regulation on Human Immunodeficiency Virus Type 1-Specific CD8 <sup>+</sup> T-Cell Cytolytic Activity and Cytokine Production," <i>J. Virol.</i> , 76(15): 7535-7543 (2002).
	C98	van Baren, N., <i>et al.</i> , "Tumoral and Immunologic Response After Vaccination of Melanoma Patients with an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells," <i>J. Clin. Oncol.</i> , 23(35): 9008-9021 (2005).
	C99	Vuola, J.M., <i>et al.</i> , "Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers," <i>J. Immunol.</i> , 174(1): 449-455 (2005).
	C100	Wang, X., <i>et al.</i> , "Cellular Immune Responses to Helper-Free HSV-1 Amplicon Particles Encoding HIV-1 gp120 are Enhanced by DNA Priming," <i>Vaccine</i> , 21(19-20): 2288-2297 (2003).
	C101	Woodberry, T., <i>et al.</i> , "Prime Boost Vaccination Strategies: CD8 T Cell Numbers, Protection, and Th1 Bias," <i>J. Immunol.</i> , 170: 2599-2604 (2003).
	C102	Zajac, P., <i>et al.</i> , "Phase I/II Clinical Trial of a Nonreplicative Vaccinia Virus Expressing Multiple HLA-A0201-Restricted Tumor-Associated Epitopes and Costimulatory Molecules in Metastatic Melanoma Patients," <i>Human Gene Therapy</i> , 14(16): 1497-1510 (2003).

EXAMINER /Louise Humphrey/	DATE CONSIDERED 07/02/2008
-------------------------------	-------------------------------